Reduced HBME‐1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma‐related neoplastic lesions with Hürthle cell and/or apocrine‐like changes

T, K; Bokhary, Rana; Yazdi, Hossein M.; Thomas, Justin; Commons, A S

doi:10.1046/j.1365-2559.2002.01315.x

Cited by 37 publications

(41 citation statements)

References 19 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thyrotoxic hyperplasia was consistently negative (Rossi et al, 2006) whereas nodular goitres were positive in up to 17% of cases (Ito et al, 2005). Significant reactions were also reported in 25% of thyroiditis (Prasad et al, 2005), 5 -10% of benign follicular tumours devoid of atypical features, and up to 65% with LNFPTC or Hürthle cell features (Mai et al, 2002;Papotti et al, 2005;Prasad et al, 2005;Scognamiglio et al, 2006). The fact that specificity in our study was in the lower range may be due to a high proportion of atypical or Hürthle cell tumours and absence of hyper-functional nodules.…”

Section: Discussionsupporting

confidence: 45%

“…However, overall results obtained on fresh tissue, including our study, and cell blocks are rather concordant. The sensitivity of HBME-1 staining was excellent (490%) for classical PC (van Hoeven et al, 1998;Ito et al, 2005;Rossi et al, 2005), disappointing for PCFV, and poor (o65%) for follicular and undifferentiated cancers (Cheung et al, 2001;Mai et al, 2002;Ito et al, 2005;Prasad et al, 2005;Saggiorato et al, 2005). The reported specificity of HBME-1 staining ranged from 70% to more than 90% (Cheung et al, 2001;Prasad et al, 2005;Saggiorato et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…Hector Battifora mesothelial antigen-1 immunohistochemistry is usually negative in benign thyroid lesions and positive on carcinomas. Most studies using HBME-1 for diagnosis of thyroid tumours have been performed on tissue samples (Mai et al, 2002;Ito et al, 2005;Papotti et al, 2005;Prasad et al, 2005). A few studies using FNA products have been carried out on cell blocks or thin layers (Sack et al, 1997;van Hoeven et al, 1998;Rossi et al, 2005;Saggiorato et al, 2005).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV

Micco¹,

Савченко²,

Giorgi

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

The purpose of this study was to compare the diagnostic interest of Hector Battifora mesothelial antigen-1 (HBME-1), thyroid peroxidase (TPO), and dipeptidyl aminopeptidase IV (DPP4) in thyroid fine-needle aspirates obtained from 200 resected thyroid lesions (55 colloid nodules, 54 follicular adenomas, 59 papillary cancers, and 32 follicular carcinomas). Hector Battifora mesothelial antigen-1 or TPO expression (% positive cells) and DPP4 staining score (12-point scale) were evaluated. Receiver operating characteristic (ROC) curves were plotted and optimal cutoff values for diagnosing malignancy were determined. The TPO ROC curve was consistently higher than the HBME-1 ROC curve. The TPO curve was also higher than the DPP4 curve with regard to sensitivity, but dipped below the DPP4 curve with regard to specificity. Using a cutoff value of o80% positive cells for TPO, 410% positive cells for HBME-1, and staining score X1 for DPP4, sensitivity to specificity ratios were 98 -83% for TPO, 90 -60% for HBME-1, and 88 -80% for DPP4. Two particularly interesting findings of this study were the low negative likelihood ratio of TPO (0.02) allowing highly reliable exclusion of malignancy and the 100% specificity of DPP4 staining scores ¼ 12. Due to poor performance on follicular lesions, HBME-1 showed no advantage over TPO or DPP4.

show abstract

Section: Discussionsupporting

confidence: 45%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV

Micco¹,

Савченко²,

Giorgi

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In recent years, many papers have been published on the identification of protein markers to improve the differential diagnosis of thyroid lesions, using both a candidate marker and an unbiased approach (4)(5)(6)(7)(8)(9)(10)(11)(12). Despite the considerable variability in the outcomes of these studies, some promising protein markers for the differential diagnosis of thyroid neoplastic lesions have emerged, including galectin-3 (Gal-3) (4,(12)(13)(14)(15)(16)(17)(18) and Hector Battifora mesothelial (HBME-1) (18)(19)(20)(21)(22)(23). has been found to be strongly and diffusely expressed in papillary thyroid carcinoma (PTC), whereas it is heterogeneously expressed in follicular thyroid carcinoma (FTC) and absent or focally expressed in follicular adenoma (FA) (18,(24)(25)(26)(27)(28)(29).…”

Section: Introductionmentioning

confidence: 99%

Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma

Liu¹,

Morreau²,

Kievit³

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology. This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E-and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-g, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms. Our study differed from earlier ones with regard to the identification of optimal semiquantitative cut-off levels using receiver operator curve (ROC) analysis and hierarchical cluster analysis. Methods: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)). Antibody staining was scored semiquantitatively based on the ROC analyses and with hierarchical cluster analysis. Results: In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, HBME-1, and iNIS in malignant thyroid lesions. Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions. A panel of Gal-3, FN-1, and iNIS, identified by hierarchical cluster analysis, had a 98% accuracy to differentiate between FA and malignant thyroid lesions. In addition, HBME-1 was found to be useful in the differentiation between FA and FVPTC (accuracy 88%). Conclusion: We conclude that identifying optimal antibody panels with cluster analysis increases the diagnostic value in the differential diagnosis of thyroid neoplasms, the combination of FN-1, Gal-3, and iNIS having the best accuracy (98%). 158 375-384 European Journal of Endocrinology

show abstract

“…Depending on the severity of these changes and the bias of the observer, terms such as atypical adenoma, 'hybrid' carcinoma, and-more recentlywell-differentiated carcinoma not otherwise specified were proposed. [1][2][3][4][5] In a recent editorial from the Chernobyl Pathologists Group the suggestion was made to label tumors with 'borderline' features as well-differentiated tumor of uncertain malignant potential (WDT-UMP) in the presence of questionable papillary carcinoma-type nuclear changes with or without questionable capsular penetration, or follicular tumor of uncertain malignant potential (FT-UMP) in the presence of questionable capsular penetration without nuclear changes. 6,7 Several immunocytochemical markers of malignancy have been claimed to be useful to distinguish follicular adenoma from carcinoma and also to identify papillary carcinoma and its variants, both in surgical and cytological specimens.…”

mentioning

confidence: 99%

Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential

Rodríguez²,

et al. 2005

View full text Add to dashboard Cite

Well-differentiated encapsulated tumors of the thyroid gland with a follicular architecture may cause diagnostic difficulties. Questionable vascular or capsular penetration may raise the possibility of a follicular carcinoma, while focal nuclear clearing and grooves may suggest a diagnosis of papillary carcinoma. A proposal has recently been made to designate cases showing suggestive but not conclusive morphological evidence of malignancy along these lines as well-differentiated or follicular tumors of uncertain malignant potential. The aim of the present study was to investigate the expression and diagnostic role in well-differentiated or follicular tumors of uncertain malignant potential of Galectin-3 and HBME-1, two malignancy-related markers. A total of 21 tumors fulfilling the criteria of well-differentiated or follicular tumors of uncertain malignant potential were collected from two institutions, including eight cases with questionable vascular and/or capsular invasion and 13 cases with some degree of nuclear changes in the form of clearing, grooves, and/or pseudoinclusions. Tumors in the first group expressed HBME-1 and Galectin-3 focally (less than 25% of tumor cells) in 5/8 and 3/8 cases, respectively, with 62.5% of cases reacting for at least one marker. Cases in the second category expressed HBME-1 and Galectin-3 in 9/13 and 10/13 cases, respectively, with 92.3% of cases having at least one marker expressed. These findings indicate that HBME-1 and Galectin-3 are heterogeneously distributed in these borderline tumors, but that a strong and diffuse expression of HBME-1 and to a lower extent of Galectin-3 was preferentially observed in the group characterized by nuclear changes which were similar but less developed than those of conventional papillary carcinoma. The relationship found between the markers investigated and these nuclear changes suggests that the tumors containing them are pathogenetically linked to papillary carcinomas.

show abstract

Reduced HBME‐1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma‐related neoplastic lesions with Hürthle cell and/or apocrine‐like changes

Cited by 37 publications

References 19 publications

Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV

Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV

Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma

Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential

Contact Info

Product

Resources

About